Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
Market Analysis and Insights: Global Scleroderma Therapeutics Market
The global Scleroderma Therapeutics market is projected to grow from US$ 1495 million in 2024 to US$ 1827.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Scleroderma Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Scleroderma Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Scleroderma Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Scleroderma Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Scleroderma Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Scleroderma Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
Segment by Type
Immunosuppressors
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Segment by Application
Systemic
Localized
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Scleroderma Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Scleroderma Therapeutics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Scleroderma Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Immunosuppressors
1.2.3 Phosphodiesterase 5 Inhibitors - PHA
1.2.4 Endothelin Receptor Antagonists
1.2.5 Prostacyclin Analogues
1.2.6 Calcium Channel Blockers
1.2.7 Analgesics
1.2.8 Others
1.3 Market by Application
1.3.1 Global Scleroderma Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Systemic
1.3.3 Localized
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Scleroderma Therapeutics Market Perspective (2019-2030)
2.2 Global Scleroderma Therapeutics Growth Trends by Region
2.2.1 Scleroderma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Scleroderma Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Scleroderma Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Scleroderma Therapeutics Market Dynamics
2.3.1 Scleroderma Therapeutics Industry Trends
2.3.2 Scleroderma Therapeutics Market Drivers
2.3.3 Scleroderma Therapeutics Market Challenges
2.3.4 Scleroderma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Scleroderma Therapeutics by Players
3.1.1 Global Scleroderma Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Scleroderma Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Scleroderma Therapeutics Market Concentration Ratio
3.4.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2023
3.5 Global Key Players of Scleroderma Therapeutics Head office and Area Served
3.6 Global Key Players of Scleroderma Therapeutics, Product and Application
3.7 Global Key Players of Scleroderma Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Scleroderma Therapeutics Breakdown Data by Type
4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2025-2030)
5 Scleroderma Therapeutics Breakdown Data by Application
5.1 Global Scleroderma Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Scleroderma Therapeutics Market Size (2019-2030)
6.2 North America Scleroderma Therapeutics Market Size by Type
6.2.1 North America Scleroderma Therapeutics Market Size by Type (2019-2024)
6.2.2 North America Scleroderma Therapeutics Market Size by Type (2025-2030)
6.2.3 North America Scleroderma Therapeutics Market Share by Type (2019-2030)
6.3 North America Scleroderma Therapeutics Market Size by Application
6.3.1 North America Scleroderma Therapeutics Market Size by Application (2019-2024)
6.3.2 North America Scleroderma Therapeutics Market Size by Application (2025-2030)
6.3.3 North America Scleroderma Therapeutics Market Share by Application (2019-2030)
6.4 North America Scleroderma Therapeutics Market Size by Country
6.4.1 North America Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Scleroderma Therapeutics Market Size by Country (2019-2024)
6.4.3 North America Scleroderma Therapeutics Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Scleroderma Therapeutics Market Size (2019-2030)
7.2 Europe Scleroderma Therapeutics Market Size by Type
7.2.1 Europe Scleroderma Therapeutics Market Size by Type (2019-2024)
7.2.2 Europe Scleroderma Therapeutics Market Size by Type (2025-2030)
7.2.3 Europe Scleroderma Therapeutics Market Share by Type (2019-2030)
7.3 Europe Scleroderma Therapeutics Market Size by Application
7.3.1 Europe Scleroderma Therapeutics Market Size by Application (2019-2024)
7.3.2 Europe Scleroderma Therapeutics Market Size by Application (2025-2030)
7.3.3 Europe Scleroderma Therapeutics Market Share by Application (2019-2030)
7.4 Europe Scleroderma Therapeutics Market Size by Country
7.4.1 Europe Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Scleroderma Therapeutics Market Size by Country (2019-2024)
7.4.3 Europe Scleroderma Therapeutics Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Scleroderma Therapeutics Market Size (2019-2030)
8.2 China Scleroderma Therapeutics Market Size by Type
8.2.1 China Scleroderma Therapeutics Market Size by Type (2019-2024)
8.2.2 China Scleroderma Therapeutics Market Size by Type (2025-2030)
8.2.3 China Scleroderma Therapeutics Market Share by Type (2019-2030)
8.3 China Scleroderma Therapeutics Market Size by Application
8.3.1 China Scleroderma Therapeutics Market Size by Application (2019-2024)
8.3.2 China Scleroderma Therapeutics Market Size by Application (2025-2030)
8.3.3 China Scleroderma Therapeutics Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Scleroderma Therapeutics Market Size (2019-2030)
9.2 Asia Scleroderma Therapeutics Market Size by Type
9.2.1 Asia Scleroderma Therapeutics Market Size by Type (2019-2024)
9.2.2 Asia Scleroderma Therapeutics Market Size by Type (2025-2030)
9.2.3 Asia Scleroderma Therapeutics Market Share by Type (2019-2030)
9.3 Asia Scleroderma Therapeutics Market Size by Application
9.3.1 Asia Scleroderma Therapeutics Market Size by Application (2019-2024)
9.3.2 Asia Scleroderma Therapeutics Market Size by Application (2025-2030)
9.3.3 Asia Scleroderma Therapeutics Market Share by Application (2019-2030)
9.4 Asia Scleroderma Therapeutics Market Size by Region
9.4.1 Asia Scleroderma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Scleroderma Therapeutics Market Size by Region (2019-2024)
9.4.3 Asia Scleroderma Therapeutics Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 F. Hoffmann-La Roche AG Company Details
11.1.2 F. Hoffmann-La Roche AG Business Overview
11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2019-2024)
11.1.5 F. Hoffmann-La Roche AG Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2019-2024)
11.2.5 Bristol-Myers Squibb Company Recent Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2019-2024)
11.3.5 Celgene Corporation Recent Developments
11.4 Argentis Pharmaceuticals, LLC
11.4.1 Argentis Pharmaceuticals, LLC Company Details
11.4.2 Argentis Pharmaceuticals, LLC Business Overview
11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
11.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2019-2024)
11.4.5 Argentis Pharmaceuticals, LLC Recent Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Scleroderma Therapeutics Introduction
11.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2019-2024)
11.5.5 Bayer AG Recent Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Company Details
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
11.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2019-2024)
11.6.5 Boehringer Ingelheim International GmbH Recent Developments
11.7 Akashi Therapeutics
11.7.1 Akashi Therapeutics Company Details
11.7.2 Akashi Therapeutics Business Overview
11.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
11.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2019-2024)
11.7.5 Akashi Therapeutics Recent Developments
11.8 Prometic Life Sciences, Inc.
11.8.1 Prometic Life Sciences, Inc. Company Details
11.8.2 Prometic Life Sciences, Inc. Business Overview
11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
11.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.8.5 Prometic Life Sciences, Inc. Recent Developments
11.9 Emerald Health Pharmaceuticals
11.9.1 Emerald Health Pharmaceuticals Company Details
11.9.2 Emerald Health Pharmaceuticals Business Overview
11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
11.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2019-2024)
11.9.5 Emerald Health Pharmaceuticals Recent Developments
11.10 Kadmon Holdings, Inc.
11.10.1 Kadmon Holdings, Inc. Company Details
11.10.2 Kadmon Holdings, Inc. Business Overview
11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
11.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.10.5 Kadmon Holdings, Inc. Recent Developments
11.11 Seattle Genetics, Inc.
11.11.1 Seattle Genetics, Inc. Company Details
11.11.2 Seattle Genetics, Inc. Business Overview
11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
11.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.11.5 Seattle Genetics, Inc. Recent Developments
11.12 Cytori Therapeutics, Inc.
11.12.1 Cytori Therapeutics, Inc. Company Details
11.12.2 Cytori Therapeutics, Inc. Business Overview
11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
11.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.12.5 Cytori Therapeutics, Inc. Recent Developments
11.13 Fibrocell Science, Inc.
11.13.1 Fibrocell Science, Inc. Company Details
11.13.2 Fibrocell Science, Inc. Business Overview
11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
11.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.13.5 Fibrocell Science, Inc. Recent Developments
11.14 Chemomab
11.14.1 Chemomab Company Details
11.14.2 Chemomab Business Overview
11.14.3 Chemomab Scleroderma Therapeutics Introduction
11.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2019-2024)
11.14.5 Chemomab Recent Developments
11.15 Corbus Pharmaceuticals Holdings, Inc.
11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details
11.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview
11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
11.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)
11.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Developments
11.16 Genkyotex
11.16.1 Genkyotex Company Details
11.16.2 Genkyotex Business Overview
11.16.3 Genkyotex Scleroderma Therapeutics Introduction
11.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2019-2024)
11.16.5 Genkyotex Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
听
听
*If Applicable.
